Get started
OSE IMMUNOTHERAPEUTICSOO

OSE IMMUNOTHERAPEUTICS

6.250EURD
+0.085+1.38%
At close at Jun 4, 15:35 GMT
EUR
No trades
See on Supercharts
Overview
Financials
News Discussions Technicals Forecast Seasonals

OSE fundamentals

Key facts

Market capitalization‪137.59 M‬EUR
Dividend yield (indicated)—
Price to earnings Ratio (TTM)3.57
Basic EPS (TTM)1.73EUR
Founded2004
Employees (FY)64
CEONicolas Poirier
Websiteose-immuno.com
About

OSE Immunotherapeutics SA s is a biotechnology company, which engages in the research and development of pharmaceutical products. It focuses on developing and partnering therapies to control the immune system for immuno-oncology and immuno-inflammation. The company was founded by Dominique Constantini on November 17, 2004 and is headquartered in Nantes, France.

Ownership
‪‪22.31 M‬‬
Free Float shares
‪‪16.79 M‬‬ (75.28%)
Closely held shares
‪‪5.51 M‬‬ (24.72%)
Free Float shares
‪‪16.79 M‬‬ (75.28%)
Closely held shares
‪‪5.51 M‬‬ (24.72%)
Capital structure
Market cap
‪‪137.59 M‬‬
Debt
‪‪46.13 M‬‬
Cash & equivalents
‪‪59.12 M‬‬
Enterprise value
‪‪124.60 M‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪137.59 M‬‬
Price to earning ratio (P/E)
3.57x
Price to sales ratio (P/S)
1.93x
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
3.57x
Price to sales ratio (P/S)
1.93x
Valuation ratios
‪0.00‬
‪10.00‬
‪20.00‬
‪30.00‬
‪40.00‬
H2 '22
H1 '23
H2 '23
H1 '24
H2 '24
‪0.00‬
‪1.10‬
‪2.20‬
‪3.30‬
‪4.40‬
P/E
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪−2,400.0%‬
‪−1,600.0%‬
‪−800.0%‬
‪0.0%‬
‪800.0%‬
H2 '22
H1 '23
H2 '23
H1 '24
H2 '24
‪‪−25.00 M‬‬
‪0.00‬
‪‪25.00 M‬‬
‪‪50.00 M‬‬
‪‪75.00 M‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪‪−24.00 M‬‬
‪‪−16.00 M‬‬
‪‪−8.00 M‬‬
‪0.00‬
‪‪8.00 M‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪‪−21.00 M‬‬
‪‪−14.00 M‬‬
‪‪−7.00 M‬‬
‪0.00‬
‪‪7.00 M‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2024
Pharmaceutical Products
By country
Period: 2024
France

Estimates

Revenue and Earnings forecasts and estimates accuracy

Revenue
H1 '23
H2 '23
H1 '24
H2 '24
H1 '25
‪0.00‬
‪‪21.00 M‬‬
‪‪42.00 M‬‬
‪‪63.00 M‬‬
‪‪84.00 M‬‬
Actual
Earnings
Next:Sep 25, 2025
H1 '23
H2 '23
H1 '24
H2 '24
H1 '25
‪−0.64‬
‪−0.48‬
‪−0.32‬
‪−0.16‬
‪0.00‬
Actual

Dividends

Dividend yield, history and sustainability

No dividends
OSE has never paid dividends and has no current plans to do so.

Financial health

Financial position and solvency of the company

Debt level and coverage
H2 '22
H1 '23
H2 '23
H1 '24
H2 '24
‪‪−26.00 M‬‬
‪0.00‬
‪‪26.00 M‬‬
‪‪52.00 M‬‬
‪‪78.00 M‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪20.00 M‬‬
‪‪40.00 M‬‬
‪‪60.00 M‬‬
‪‪80.00 M‬‬
Assets
Liabilities